Cargando…

Risk of Severe COVID-19 in Non-Adherent OSA Patients

BACKGROUND: Patients with obstructive sleep apnoea (OSA) are at increased risk of severe course of COVID-19. Vaccination remains to be the most effective prevention of complicated courses of infection. The best contemporary conservative treatment of OSA is continuous positive airway pressure (CPAP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Genzor, Samuel, Prasko, Jan, Mizera, Jan, Jakubec, Petr, Sova, Milan, Vanek, Jakub, Šurinová, Nikoleta, Langova, Katerina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657257/
https://www.ncbi.nlm.nih.gov/pubmed/36387050
http://dx.doi.org/10.2147/PPA.S387657
_version_ 1784829646910521344
author Genzor, Samuel
Prasko, Jan
Mizera, Jan
Jakubec, Petr
Sova, Milan
Vanek, Jakub
Šurinová, Nikoleta
Langova, Katerina
author_facet Genzor, Samuel
Prasko, Jan
Mizera, Jan
Jakubec, Petr
Sova, Milan
Vanek, Jakub
Šurinová, Nikoleta
Langova, Katerina
author_sort Genzor, Samuel
collection PubMed
description BACKGROUND: Patients with obstructive sleep apnoea (OSA) are at increased risk of severe course of COVID-19. Vaccination remains to be the most effective prevention of complicated courses of infection. The best contemporary conservative treatment of OSA is continuous positive airway pressure (CPAP) therapy. PURPOSE: To compare vaccination acceptance and outcomes of COVID-19 infection between OSA patients adhering to the CPAP therapy and those who rejected CPAP and surgical therapy. PATIENTS AND METHODS: Subjects were divided into two groups: group A (N = 167) were individuals with sufficient CPAP adherence (more than 4 hours per night on average) over the last 10 years. Group B (N = 106) were individuals who did not use the CPAP therapy at all and had no indications to surgical therapy. RESULTS: Three patients in group B died, and one had a severe course of COVID-19. None of the patients in group A died or experienced a severe course of COVID-19. Group A had a significantly higher proportion of males (77.8% compared to 66% in group B) and all parameters of OSA severity. The vaccination status was similar among both groups, with a complete triple dose vaccination rate of 69.5% and 67.9% in groups A and B, respectively. CONCLUSION: The results show that the patients with OSA adherent to CPAP therapy were less likely to experience a severe course of COVID-19 or death than the OSA patients non-compliant with therapy, despite the former group having more severe OSA. This result underlines the importance of adherence to CPAP therapy in OSA.
format Online
Article
Text
id pubmed-9657257
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96572572022-11-15 Risk of Severe COVID-19 in Non-Adherent OSA Patients Genzor, Samuel Prasko, Jan Mizera, Jan Jakubec, Petr Sova, Milan Vanek, Jakub Šurinová, Nikoleta Langova, Katerina Patient Prefer Adherence Original Research BACKGROUND: Patients with obstructive sleep apnoea (OSA) are at increased risk of severe course of COVID-19. Vaccination remains to be the most effective prevention of complicated courses of infection. The best contemporary conservative treatment of OSA is continuous positive airway pressure (CPAP) therapy. PURPOSE: To compare vaccination acceptance and outcomes of COVID-19 infection between OSA patients adhering to the CPAP therapy and those who rejected CPAP and surgical therapy. PATIENTS AND METHODS: Subjects were divided into two groups: group A (N = 167) were individuals with sufficient CPAP adherence (more than 4 hours per night on average) over the last 10 years. Group B (N = 106) were individuals who did not use the CPAP therapy at all and had no indications to surgical therapy. RESULTS: Three patients in group B died, and one had a severe course of COVID-19. None of the patients in group A died or experienced a severe course of COVID-19. Group A had a significantly higher proportion of males (77.8% compared to 66% in group B) and all parameters of OSA severity. The vaccination status was similar among both groups, with a complete triple dose vaccination rate of 69.5% and 67.9% in groups A and B, respectively. CONCLUSION: The results show that the patients with OSA adherent to CPAP therapy were less likely to experience a severe course of COVID-19 or death than the OSA patients non-compliant with therapy, despite the former group having more severe OSA. This result underlines the importance of adherence to CPAP therapy in OSA. Dove 2022-11-09 /pmc/articles/PMC9657257/ /pubmed/36387050 http://dx.doi.org/10.2147/PPA.S387657 Text en © 2022 Genzor et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Genzor, Samuel
Prasko, Jan
Mizera, Jan
Jakubec, Petr
Sova, Milan
Vanek, Jakub
Šurinová, Nikoleta
Langova, Katerina
Risk of Severe COVID-19 in Non-Adherent OSA Patients
title Risk of Severe COVID-19 in Non-Adherent OSA Patients
title_full Risk of Severe COVID-19 in Non-Adherent OSA Patients
title_fullStr Risk of Severe COVID-19 in Non-Adherent OSA Patients
title_full_unstemmed Risk of Severe COVID-19 in Non-Adherent OSA Patients
title_short Risk of Severe COVID-19 in Non-Adherent OSA Patients
title_sort risk of severe covid-19 in non-adherent osa patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657257/
https://www.ncbi.nlm.nih.gov/pubmed/36387050
http://dx.doi.org/10.2147/PPA.S387657
work_keys_str_mv AT genzorsamuel riskofseverecovid19innonadherentosapatients
AT praskojan riskofseverecovid19innonadherentosapatients
AT mizerajan riskofseverecovid19innonadherentosapatients
AT jakubecpetr riskofseverecovid19innonadherentosapatients
AT sovamilan riskofseverecovid19innonadherentosapatients
AT vanekjakub riskofseverecovid19innonadherentosapatients
AT surinovanikoleta riskofseverecovid19innonadherentosapatients
AT langovakaterina riskofseverecovid19innonadherentosapatients